| Literature DB >> 32724245 |
Jinfei Li1, Huijin Ye1, Weihua Shen1, Qianru Chen1, Yiquan Lin1, Xiaoliang Gan1.
Abstract
BACKGROUND AND AIMS: Postoperative nausea and vomiting (PONV), one of the common complications following strabismus surgery, would delay the ambulatory discharge time. The aim of this retrospective study was to determine the risk factors of PONV in patients undergoing ambulatory strabismus surgery under general anaesthesia, with the treatments of dexamethasone and 5-HT3 antagonist combination.Entities:
Keywords: Anaesthesia; ophthalmic; postoperative nausea and vomiting
Year: 2020 PMID: 32724245 PMCID: PMC7286407 DOI: 10.4103/ija.IJA_16_20
Source DB: PubMed Journal: Indian J Anaesth ISSN: 0019-5049
Demographic and clinical characteristics
| Clinical values | |
|---|---|
| PONV, No. (%) | |
| Absent | 699 (96.95%) |
| Present | 22 (3.05%) |
| Gender, No. (%) | |
| Male | 361 (50.07%) |
| Female | 360 (49.93%) |
| Age (y), median (IQR) | 24.00 (19.00-31.00) |
| Height (cm), median (IQR) | 164.00 (158.00-170.00) |
| Weight (kg), median (IQR) | 55.00 (49.00-65.00) |
| Duration of surgery (min), median (IQR) | 27.00 (20.00-35.00) |
| Recovery period I (min), median (IQR) | 30.00 (21.50-40.00) |
| Recovery period II (min), median (IQR) | 35.00 (20.00-61.50) |
| ASA-grade, median (IQR) | 1.00 (1.00-1.00) |
| I, No. (%) | 652 (90.43%) |
| II, No. (%) | 69 (9.57%) |
| LMA size, median (IQR) | 4.00 (4.00-4.00) |
| 2, No. (%) | 4 (0.55%) |
| 2.5, No. (%) | 2 (0.28%) |
| 3, No. (%) | 82 (11.37%) |
| 4, No. (%) | 507 (70.32%) |
| 5, No. (%) | 126 (17.48%) |
| Surgical eye, No. (%) | |
| Left only | 266 (36.89%) |
| Right only | 249 (34.54%) |
| Bilateral | 206 (28.57%) |
| Intravenous or inhalational anaesthesia, No. (%) | |
| Intravenous anaesthesia | 615 (85.30%) |
| Inhalational anaesthesia | 106 (14.70%) |
| Using sevoflurane | 17 (2.36%) |
| Using desflurane | 89 (12.34%) |
| Using dexmedetomidine, No. (%) | 221 (30.65%) |
| Using dexamethasone, No. (%) | 721 (100.00%) |
| Using midazolam, No. (%) | 291 (40.36%) |
| 5-HT3 antagonist, No. (%) | |
| Using tropisetron | 498 (69.07%) |
| Using palonosetron | 223 (30.93%) |
| Assistant analgesic, No. (%) | |
| Using flurbiprofen axetil | 470 (65.19%) |
| Using nalbuphine | 251 (34.81%) |
| Surgical superior rectus muscle, No. (%) | |
| Unilateral | 43 (5.96%) |
| Bilateral | 5 (0.69%) |
| Surgical inferior rectus muscle, No. (%) | |
| Unilateral | 30 (4.16%) |
| Bilateral | 12 (1.66%) |
| Surgical superior oblique muscle, No. (%) | |
| Unilateral | 41 (5.69%) |
| Bilateral | 9 (1.25%) |
| Surgical inferior oblique muscle, No. (%) | |
| Unilateral | 56 (7.77%) |
| Bilateral | 20 (2.77%) |
| Surgical medial rectus muscle, No. (%) | |
| Unilateral | 389 (53.95%) |
| Bilateral | 10 (1.39%) |
| Surgical lateral rectus muscle, No. (%) | |
| Unilateral | 457 (63.38%) |
| Bilateral | 152 (21.08%) |
| Sum of surgical extraocular muscles, Median (IQR) | 2.00 (2.00-2.00) |
| 1, No. (%) | 163 (22.61%) |
| 2, No. (%) | 428 (59.36%) |
| 3, No. (%) | 110 (15.26%) |
| 4, No. (%) | 19 (2.64%) |
| 5, No. (%) | 1 (0.14%) |
PONV–Postoperative nausea and vomiting; recovery period I: end of operation→Exit from post-anaesthesia care unit (PACU); Recovery period I: Exit from PACU→post-anaesthesia discharge score (PADS) met 9; ASA–American Society of Anesthesiologists; LMA–Laryngeal mask airway; IQR–Interquartile range
Single-factor analysis results
| PONV, No. (%) | Absent, 699 (96.95%) | Present, 22 (3.05%) | |
|---|---|---|---|
| Age (y)a, median (IQR) | 24.00 (19.00-31.00) | 20.50 (16.50-24.75) | 0.04 |
| Height (cm)a, median (IQR) | 164.00 (158.00-170.00) | 160.50 (157.75-170.75) | 0.53 |
| Weight (kg)a, median (IQR) | 55.00 (49.00-65.00) | 55.50 (44.75-66.00) | 0.43 |
| Duration of surgery (min)a, median (IQR) | 26.00 (20.00-35.00) | 33.00 (19.50-41.50) | 0.15 |
| Recovery period I (min)a, median (IQR) | 30.00 (22.00-40.00) | 26.00 (20.00-37.25) | 0.37 |
| Recovery period II (min)a, median (IQR) | 35.00 (20.00-60.00) | 56.00 (29.50-95.50) | 0.006 |
| LMA sizea, No. (%) | 4.00 (4.00-4.00) | 4.00 (4.00-4.00) | 0.35 |
| 2, No. (%) | 4 (0.57%) | 0 (0%) | |
| 2.5, No. (%) | 2 (0.29%) | 0 (0%) | |
| 3, No. (%) | 80 (11.44%) | 2 (9.09%) | |
| 4, No. (%) | 488 (69.81%) | 19 (86.36%) | |
| 5, No. (%) | 125 (17.88%) | 1 (4.55%) | |
| Genderb, No. (%) | 0.09 | ||
| Female | 345 (49.36%) | 15 (68.18%) | |
| Male | 354 (50.64%) | 7 (31.82%) | |
| ASA-gradea, median (IQR) | 1.00 (1.00-1.00) | 1.00 (1.00-1.00) | 0.51 |
| Ⅰ, No. (%) | 631 (90.27%) | 21 (95.45%) | |
| Ⅰ, No. (%) | 68 (9.73%) | 1 (4.55%) | |
| Surgical eyeb, No. (%) | 0.86 | ||
| Left | 257 (36.77%) | 9 (40.91%) | |
| Right | 241 (34.48%) | 8 (36.36%) | |
| Bilateral | 201 (28.76%) | 5 (22.73%) | |
| Intravenous or inhalational anaesthesiab, No. (%) | |||
| Intravenous anaesthesia | 594 (84.98%) | 21 (95.45%) | 0.23 |
| Inhalational anaesthesia | 105 (15.02%) | 1 (4.55%) | |
| Using sevoflurane | 17 (16.19%) | 0 (0%) | >0.99 |
| Using desflurane | 88 (83.81%) | 1 (100%) | |
| Using dexmedetomidineb, No. (%) | 214 (30.62%) | 7 (31.82%) | >0.99 |
| Using dexamethasoneb, No. (%) | 699 (100%) | 22 (100%) | - |
| Using midazolamb, No. (%) | 277 (39.63%) | 14 (63.64%) | 0.03 |
| 5-HT3 antagonistb, No. (%) | |||
| Using tropisetron | 477 (68.24%) | 21 (95.45%) | 0.004 |
| Using palonosetron | 222 (31.76%) | 1 (4.55%) | |
| Analgesicb, No. (%) | |||
| Using flurbiprofen axetil | 463 (66.24%) | 7 (31.82%) | 0.002 |
| Using nalbuphine | 236 (33.76%) | 15 (68.18%) | |
| Surgical superior rectus musclea, No. (%) | 0.052 | ||
| Unilateral | 59 (4.39%) | 5 (15%) | |
| Bilateral | 11 (0.82%) | 0 (0%) | |
| Surgical inferior rectus musclea, No. (%) | 0.51 | ||
| Unilateral | 50 (3.72%) | 2 (6%) | |
| Bilateral | 19 (1.41%) | 2 (6%) | |
| Surgical superior oblique musclea, No. (%) | 0.39 | ||
| Unilateral | 63 (4.69%) | 4 (12%) | |
| Bilateral | 22 (1.64%) | 0 (0%) | |
| Surgical inferior oblique musclea, No. (%) | 0.63 | ||
| Unilateral | 130 (9.67%) | 2 (6%) | |
| Bilateral | 44 (3.27%) | 3 (9%) | |
| Surgical medial rectus musclea, No. (%) | 0.13 | ||
| Unilateral | 633 (47.10%) | 24 (71%) | |
| Bilateral | 33 (2.46%) | 0 (0%) | |
| Surgical lateral rectus musclea, No. (%) | 0.49 | ||
| Unilateral | 842 (62.65%) | 15 (44%) | |
| Bilateral | 269 (20.02%) | 11 (32%) | |
| Sum of surgical extraocular musclesa, Median (IQR) | 2.00 (2.00-2.00) | 2.00 (2.00-3.00) | 0.001 |
| 1, No. (%) | 161 (22.03%) | 2 (9.09%) | |
| 2, No. (%) | 418 (59.80%) | 10 (45.45%) | |
| 3, No. (%) | 103 (14.74%) | 7 (31.82%) | |
| 4, No. (%) | 16 (2.29%) | 3 (13.64%) | |
| 5, No. (%) | 1 (0.14%) | 0 (0%) |
aBy Mann-Whitney U test with two-side, bBy Fisher’s exact test with two-sides, PONV–Postoperative nausea and vomiting; recovery period Ⅰ: End of operation→Exit from PACU; recovery period Ⅰ: Exit from PACU→PADS met 9; ASA–American Society of Anesthesiologists; LMA–Laryngeal mask airway; IQR–Interquartile range
Propensity score matching results
| PONV | Absent | Present | OR (95% CI) | PSM Overall Balance Test (Hansen and Bowers) γ2 ( | |
|---|---|---|---|---|---|
| Gender, No. (%) | |||||
| Male | 316 (50.64%) | 7 (31.82%) | 0.13 | 2.20 (0.88, 5.47) | 2.61 (0.98) |
| Female | 308 (49.36%) | 15 (68.18%) | |||
| Using midazolam, No. (%) | 168 (49.12%) | 9 (75.00%) | 0.14 | 3.11 (0.83, 11.68) | 12.15 (0.15) |
| 5-HT3 antagonist, No. (%) | |||||
| Using tropisetron | 92 (50.27%) | 0 (0%) | >0.99 | 1.01 (0.99, 1.03) | 9.50 (0.39) |
| Using palonosetron | 91 (49.73%) | 1 (100%) | |||
| Assistant analgesic, No. (%) | |||||
| Using flurbiprofen axetil | 160 (51.61%) | 3 (18.75%) | 0.02 | 4.62 (1.29, 16.54) | 9.44 (0.31) |
| Using nalbuphine | 150 (48.39%) | 13 (81.25%) | |||
| Binary surgical superior rectus muscle, No. (%) | 40 (48.19%) | 4 (80%) | 0.36 | 4.30 (0.46, 40.12) | 3.44 (0.90) |
All hypothesis by Fisher’s exact test with two-sides after respective PSM. PSM–Propensity score matching; PONV–Postoperative nausea and vomiting
Binary logistic regression of multi factors results
| PONV | β Coefficient | SE | EXP (β)/OR (95% CI) | Omnisbus Test γ2 ( | Hosmer-Lemeshow Test γ2 ( | Nagelkerke | |
|---|---|---|---|---|---|---|---|
| Nalbuphine (versus flurbiprofen axetil) | 1.37 | 0.47 | 0.004 | 3.93 (1.56, 9.87) | 23.52 (<0.001) | 7.35 (0.50) | 0.13 |
| Age | -0.05 | 0.03 | 0.09 | 0.95 (0.90, 1.00) | |||
| Sum of surgical extraocular muscles | 0.89 | 0.27 | 0.001 | 2.44 (1.42, 4.21) |
All regression hypothesis tests are two-sided. PONV–Postoperative nausea and vomiting; IQR–Interquartile range
Figure 1Receiver operating characteristic (ROC) curve for the model of risk factors: female; sum of surgical extraocular muscles; nalbuphine (vs flurbiprofen axetil). P < 0.001, AUC = 0.80 (95% C.I. 0.73–0.87). Logit (P) = −5.00 + 0.89 × [sum of surgical extraocular muscles] + 1.37 × 1 [if using nalbuphine (vs flurbiprofen axetil)]